Science Journal of University of Zakho https://sjuoz.uoz.edu.krd/index.php/sjuoz <p>SJUOZ is the scientific journal of the University of Zakho with p-ISSN: 2663-628X, e-ISSN: 2663-6298 and DOI: <a href="http://doi.org/10.25271/sjuoz" target="_blank" rel="noopener">doi.org/10.25271/sjuoz</a>. SJUOZ is an international, multidisciplinary, peer-reviewed, double-blind and open-access journal. It aims to cover broader scientific research activities in the field of biology, chemistry, physics, mathematics and computer sciences. It is also committed in making genuine contributions to the science researches by providing an open access platform.</p> <p>Publication advantages in SJUOZ:</p> <p>1- Free publication charges for international authors.</p> <p>2- Constructive peer-review.</p> <p>3- Open access journal (global visibility). </p> <p>4- Easy online submission.</p> <p>5- Time to first decision 10-20 days.</p> <p>6- Free English language proof-reeding.</p> <p> </p> <p><iframe class="ginger-extension-definitionpopup" style="left: 117.4px; top: -55.6px; z-index: 100001; display: none;" src="chrome-extension://kdfieneakcjfaiglcfcgkidlkmlijjnh/content/popups/definitionPopup/index.html?title=engineering&amp;description=the%20practical%20application%20of%20science%20to%20commerce%20or%20industry"></iframe></p> University of Zakho en-US Science Journal of University of Zakho 2663-628X <h4>Authors who publish with this journal agree to the following terms:</h4> <ul> <li class="show" style="text-align: justify;">Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [<a href="https://creativecommons.org/licenses/by-nc-sa/4.0/" target="_blank" rel="noopener">CC BY-NC-SA 4.0</a>] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.</li> <li class="show" style="text-align: justify;">Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work, with an acknowledgment of its initial publication in this journal.</li> <li class="show" style="text-align: justify;">Authors are permitted and encouraged to post their work online.</li> </ul> IDENTIFICATION OF SALMONELLA TYPHIMURIUM AND SALMONELLA ENTERITIDIS IN THE IMPORTED FROZEN POULTRY https://sjuoz.uoz.edu.krd/index.php/sjuoz/article/view/1260 <p>Salmonellosis, a zoonotic illness caused by Salmonella spp., is mostly transmitted to humans through the consumption of raw animal products, particularly poultry meat. Salmonella enterica serovar Typhimurium and Salmonella enterica serovar Enteritidis are the predominant strains responsible for human infection. This study aimed to assess the prevalence of S. Enteritidis and S. Typhimurium infection in frozen imported poultry using a triplex PCR technique. A total of 110 samples were chosen using the cluster sampling technique from the Ibrahim Khalil border throughout the summer and autumn of 2023. Following the cultivation of the meat samples in enrichment and selective media, suspicious colonies were obtained. Subsequently, DNA extraction was conducted, and the Salmonella isolates were identified using triplex PCR. Three (3) sets of primer pairs were utilised to target the invA gene for the Salmonella genus, the prot6 gene for the S. enteritidis serovar, and the fliC gene for the S. typhimurium serovar. The prevalence of Salmonella infection in frozen poultry meat was 12% (13 out of 110 samples). Among the contaminated samples, 38% (5 out of 13) were recognised as S. enteritidis and 30% (4 out of 13) were recognised as S. typhimurium. The findings of this finding suggest that frozen poultry meat pose a significant danger for zoonotic infections caused by S. typhimurium. and S. enteritidis.</p> Mohammed M. Ibrahim Copyright (c) 2024 Mohammed M. Ibrahim https://creativecommons.org/licenses/by/4.0 2024-04-24 2024-04-24 12 2 149 152 10.25271/sjuoz.2024.12.2.1260 THE SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC LEUKAEMIA: A SINGLE CENTRE STUDY https://sjuoz.uoz.edu.krd/index.php/sjuoz/article/view/1240 <p>In Acute lymphoblastic Leukemia (ALL) assessment of molecular response to treatment, assessing minimal residual disease (MRD) is a major independent predictor of treatment outcome. Consequently, MRD is implemented in all ALL-treatment protocols to fill up or to redefine stratification of multifactorial risk with optional intensity of customized treatment.</p> <p>Aim: to specify the significance of MRD in the assessment of remission in children with ALL with results discordant between morphology and flow cytometry at the end of induction phase of therapy.</p> <p>Materials and Methods: A descriptive cross-sectional study was conducted at Jin Oncology Center from March 2019 through November 2023. Data were taken out of the records of 58 patients who had ALL less than 16 years old. All patients were less than 16 years old and treated by ukall. They were diagnosed using peripheral blood morphology, bone marrow study and/or flow cytometry when lymphoblasts in peripheral blood or bone marrow aspirate are ≥20% and was confirmed by flow cytometry. On 29th day of induction therapy, bone marrow was examined for morphology and flow cytometry. The presence or absence of MRD was determined, and CD19, CD10 and tdt were tested. By morphologic assessment they were divided patients into: Category 1, C1 (&lt;5% blasts), Category 2, C2 (5-20% blasts), and Category 3, C3 (&gt;20% blasts). Statistical analysis was made using SPSS version 25. P value of less than 0.05 was considered significant.</p> <p>Results: The study involved 58 patients who had ALL. with a median age of 6.5 years, male to females ratio of 1.76:1, mean platelet count of 96.6 x 10⁹/L ,mean hemoglobin of 8.6 g/dL, mean leucocyte count of 74.3 x 10⁹/L), 48 cases (82.7%) of B-cell lineage and 10 cases (17.3%) of T-cell lineage, 94.6% of the B-cell cases were of the common B-ALL and the rest Pro-BALL type, 54.6% of the T-cell ALL was cortical T-ALL and 44.4% Early T-cell ALL. They were tested for MRD by morphology and flow cytometry on day 29. By morphology, 46 patients had remission but by flow only 24 cases. Seventeen cases had residual blasts &gt;5%. In 19 cases there was a discrepancy between the results of morphology and flow. Twenty-five cases (52.08% of B-cell cases) were positive for MRD by flow results. Eight of the ten cases of T-ALL (80%), were positive for MRD by flow cytometry. Among 48 cases of B-ALL, 36 were in C1 category (morphologically in remission), 11 cases were in C2 category and one case in the C3 category. Of cases in C1 category, 17 were MRD +ve and 19 were MRD –ve by flow cytometry. In the C2 category, only 2 out of the 11 cases (18.18%) had discordant results between morphology and flow results. The correlation between morphology and flow results was 100% in the C3 category.</p> <p>Conclusion: MRD should not be the surrogate of morphology but to be used in conjunction in order to give us a more accurate representation of status of remission.</p> Abdulrahman A. Muhsin Akrem M. Atrushi Adnan A. Al-Doski Copyright (c) 2024 Abdulrahman A. Muhsin, Akrem M. Atrushi , Adnan A. Al-Doski https://creativecommons.org/licenses/by/4.0 2024-04-09 2024-04-09 12 2 144 148 10.25271/sjuoz.2024.12.2.1240